

#13C  
dia  
9/4/03  
Patent

Attorney's Docket No. 032751-066

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of )  
 )  
Pierre LEROY ) Group Art Unit: 1632  
 )  
Application No.: 09/927,933 ) Examiner: Scott D. Priebe  
 )  
Filed: August 13, 2001 ) Confirmation No.: 6916  
 )  
For: NOVEL IMPLANT AND NOVEL )  
VECTOR FOR THE TREATMENT OF )  
ACQUIRED DISEASES )

RECEIVED  
MAR 03 2003  
TECH CENTER 1600/2900

**REPLY TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is a Reply To Restriction Requirement for the above-identified patent application.

- ☐ A Petition for Extension of Time is also enclosed.
- ☐ A Terminal Disclaimer and a check for ☐ \$55.00 (2814) ☐ \$110.00 (1814) to cover the requisite Government fee are also enclosed.
- ☐ Also enclosed is \_\_\_\_\_
- ☐ Small entity status is hereby claimed.
- ☐ Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the ☐ \$370.00 (2801) ☐ \$740.00 (1801) fee due under 37 C.F.R. § 1.17(e).
- ☐ Applicant(s) previously submitted \_\_\_, on \_\_\_, for which continued examination is requested.
- ☐ Applicant(s) request suspension of action by the Office until at least \_\_\_, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.
- ☐ A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.
- ☒ No additional claim fee is required.

(10/02)

☐ An additional claim fee is required, and is calculated as shown below:

AMENDED CLAIMS					
	NO. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADD'T'L FEE
Total Claims		MINUS =		× \$18.00 (1202) =	
Independent Claims		MINUS =		× \$84.00 (1201) =	
If Amendment adds multiple dependent claims, add \$280.00 (1203)					
Total Amendment Fee					
If small entity status is claimed, subtract 50% of Total Amendment Fee					
TOTAL ADDITIONAL FEE DUE FOR THIS AMENDMENT					


☐ A claim fee in the amount of \$\_\_\_\_\_ is enclosed.

☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.


Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:   
Christopher L. North, Ph.D.  
Registration No. 50,433

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: February 28, 2003



Patent  
Attorney's Docket No. 032751-066

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
Pierre LEROY	)	Group Art Unit: 1632
	)	
Application No.: 09/927,933	)	Examiner: Scott D. Priebe
	)	
Filed: August 13, 2001	)	Confirmation No.: 6916
	)	
For: NOVEL IMPLANT AND NOVEL	)	
VECTOR FOR THE TREATMENT	)	
OF ACQUIRED DISEASES	)	

**RECEIVED**  
MAR 03 2003  
TECH CENTER 1600/2900

**REPLY TO RESTRICTION REQUIREMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Official Action (Paper No. 12) mailed January 29, 2003 setting forth a restriction requirement, please amend the application as follows:

**IN THE CLAIMS**

Subject to the remarks below, please substitute the following complete set of pending claims for claims 40-58 as renumbered in the Official Action:

40. A recombinant adenoviral vector comprising an exogenous nucleotide sequence encoding all or part of an antibody and placed under the control of the elements necessary for its expression, wherein said antibody is modified by a toxic or immunopotentiating substance.

*Handwritten:*  
SUB  
E1